Structure Therapeutics closes $747.5 million public offering

Structure Therapeutics Inc. (NASDAQ: GPCR) completed an upsized public offering that raised approximately $747.5 million in gross proceeds before underwriting fees and expenses.

The biopharmaceutical company sold 9,961,538 American depositary shares at $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at $64.9999 per warrant. Each ADS represents three ordinary shares of the company.

The offering included the full exercise of underwriters' option to purchase up to 1,500,000 additional ADSs. Structure Therapeutics, which develops oral small molecule treatments for metabolic diseases including obesity, sold all securities in the offering.

Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets served as joint book-running managers. LifeSci Capital and Citizens Capital Markets acted as co-managers.

The offering was conducted under an automatic shelf registration statement filed with the Securities and Exchange Commission on August 6, 2025, which became effective upon filing.

Structure Therapeutics focuses on discovering and developing oral small molecule treatments for chronic metabolic conditions. The company uses a structure-based drug discovery platform to develop treatments targeting G-protein-coupled receptors.

You May Also Be Interested In

• ITG, Inc. raises $323.4M in Nasdaq IPO at $16 per share
• Third Coast Bancshares approves $30M share repurchase program
• Bending Spoons closes IPO, raises ~$954M on Nasdaq